Sell Your Contract Manufacturing Business in 2026: 5-7x EBITDA, Customer Concentration, and PE Demand

Contract manufacturing is the most customer-concentration-sensitive sub-vertical in U.S. industrial M&A. Two contract manufacturers with identical revenue, EBITDA, equipment, and certifications can trade at multiples 2-3 turns apart based entirely on customer mix. The business with one Tier-1 OEM at 50% of revenue trades at 4-4.5x with an earnout. The business with eight diversified OEMs and no top customer above 20% trades at 6.5-7x clean. Customer diversification is structurally the most important multiple work in contract manufacturing.

We work directly with 76+ active U.S. lower middle market buyers, including 38 manufacturing-focused capital partners. On the contract manufacturing side specifically, the buyer pool includes Audax Industrial Partners, KKR Industrials, Cortec Group, Sterling Group, Wynnchurch Capital, Mason Wells, GenNx360 Capital Partners, Industrial Growth Partners (IGP), Trive Capital, Arsenal Capital Partners, plus aerospace specialists for aerospace-mix CDMOs (AE Industrial, Liberty Hall, Arlington Capital), medical device specialists for medical CDMOs (Linden Capital, Patient Square, LaSalle), and family offices with industrial mandates. The buyers pay us when a deal closes — not you.

This guide is the canonical hub for selling a U.S. contract manufacturing business in 2026. It covers buyer demand, multiples by size and customer mix, the five active buyer archetypes, named PE platforms with verifiable activity, the typical sale process, the drivers of premium multiples (customer diversification, multi-year contracts, certifications, IP), the deal-killers in diligence (top customer concentration, contract assignment issues, customer-side change of control), and how a buy-side partner is structurally different from a sell-side broker. If you want a starting-point valuation range now, our free valuation calculator takes about three minutes.

“Contract manufacturing is the only sub-vertical where the buyer’s first question is ‘what’s your top customer concentration’ before they ask anything else. If your answer is below 20%, you’re a platform candidate. If it’s above 40%, you’re an earnout deal at best.”

Key Takeaways

• Contract manufacturing multiples by EBITDA size: $1-3M = 4-5.5x; $3-7M = 5-6.5x; $7-15M = 5.5-7.5x; $15M+ = 6.5-8.5x for diversified-customer platform-quality assets.
• Customer concentration is the #1 multiple driver: top customer above 30% subtracts 0.5-2x; top customer below 20% adds 0.5-1x.
• Three named PE platforms with verifiable activity: Audax Industrial Partners, KKR Industrials, Cortec Group.
• Specialty CDMO buyers: aerospace specialists (AE Industrial, Liberty Hall, Arlington) for aerospace CDMOs; medical device specialists (Linden, Patient Square, LaSalle) for medical CDMOs.
• Premium drivers: customer diversification, multi-year supply agreements with assignment provisions, end-market certifications, proprietary process IP, recurring volume vs project-based.
• Top deal-killers: customer concentration above 30%, contract assignment-restriction clauses, customer-side change-of-control provisions, IP ownership ambiguity, single-source supplier exposure for the buyer.

Why customer concentration drives everything in contract manufacturing M&A

Contract manufacturing is structurally different from OEM manufacturing in one critical way: revenue belongs to the customer, not the manufacturer. If a Tier-1 OEM customer decides to insource, dual-source, or move volume to another manufacturer, your revenue moves with them. Buyers underwrite this risk explicitly. The result is that customer concentration drives more of the multiple than any other variable — more than EBITDA size, more than certifications, more than equipment capability.

Buyers’ underwriting math on customer concentration. A PE platform underwriting a contract manufacturer with one customer at 50% of revenue models a 30-50% probability of meaningful revenue loss within the 5-year hold period (customer insourcing, dual-sourcing, or moving volume). That risk gets priced in via lower headline multiple, larger earnout structures tied to customer retention, larger indemnification escrows, and tighter R&W language. The same business with the same operations and 8 diversified customers gets a clean 5-7x deal because the diversification de-risks the underwriting.

The 12-18 month customer diversification opportunity. Owners with concentrated customer bases who go to market in 12-18 months can materially improve their multiple by intentional diversification: aggressive new-customer development, intentional volume rebalancing with concentrated customer, formalization of relationships into multi-year supply agreements. Moving from 50% top customer to 25% top customer over 18 months is realistic and can drive 1-2x of multiple uplift — on $5M EBITDA, that’s $5-10M of additional purchase price. The economic asymmetry of diversification work is enormous.

Contract manufacturing multiples in 2026: what the data shows

Contract manufacturing multiples are driven by customer concentration first, EBITDA size second, end-market and certification depth third. Customer concentration drives 1-3 turns of multiple within a band. EBITDA size determines which buyer pool is active. End-market mix and certifications drive within-band positioning. Recurring volume (predictable monthly orders) vs project-based work drives 0.5x. Multi-year supply agreement structure drives 0.25-0.75x.

Generic contract manufacturing multiples by EBITDA size in 2026: $500K-$1M EBITDA: 3.5-4.5x — SBA / search-funder territory. $1-3M EBITDA: 4-5.5x — LMM PE add-on territory. $3-7M EBITDA: 5-6.5x — deep LMM PE platform territory, full 76+ buyer pool active. $7-15M EBITDA: 5.5-7.5x — mid-market PE, family offices, public strategics in pool. $15M+ EBITDA: 6.5-8.5x for platform-quality diversified assets with strategic premiums available.

Customer concentration adjustments within band: Top customer below 15% of revenue: +0.5-1x premium. Top customer 15-20%: +0.25x. Top customer 20-25%: at par. Top customer 25-30%: -0.25 to -0.5x. Top customer 30-40%: -0.5 to -1x and earnout structures emerge. Top customer 40-50%: -1 to -1.5x and significant earnout / retention structures. Top customer above 50%: -1.5 to -2x or buyer walk.

End-market and certification adjustments: Aerospace CDMO (AS9100D + Tier-1 OEM customers): +1-2x — access to aerospace specialists. Medical device CDMO (ISO 13485 + FDA): +1-3x — access to medical device specialists. Defense CDMO (ITAR + secret-cleared): +0.5-1.5x. Industrial CDMO (ISO 9001): at par. Consumer / commodity CDMO: -0.25 to -0.75x for cyclicality and lower margins.

Process and IP adjustments: Proprietary process IP (validated processes, trade secrets, patents): +0.5-1x. Recurring volume vs project-based: +0.25-0.5x for recurring. Multi-year supply agreements with assignment provisions: +0.25-0.5x. At-will / spot-buy customer relationships: -0.25-0.5x discount.

The 5 active buyer archetypes for contract manufacturing

The buyer pool for U.S. contract manufacturing divides into five archetypes. Each archetype underwrites customer concentration differently. PE platforms care most. Strategics care less if the strategic synergy outweighs concentration risk. Family offices care moderately. Search funders care most because their personal capital is at risk.

Archetype 1: contract-mfg-active PE platform. Audax Industrial Partners — deep LMM industrial with contract manufacturing platforms. KKR Industrials — large-cap industrial with platform / add-on programs. Cortec Group — industrial including contract manufacturing exposure. Multiples: 6-8x EBITDA at platform size for diversified-customer assets. Process: full QoE with extensive customer concentration analysis. Best fit: $5M+ EBITDA contract manufacturing with top customer below 25%.

Archetype 2: generalist industrial PE. Sterling Group, Wynnchurch Capital, Mason Wells, GenNx360, Industrial Growth Partners (IGP), Trive Capital, Arsenal Capital Partners — all have contract manufacturing exposure within broader industrial portfolios. Multiples: 5-6.5x EBITDA. Best fit: $3-15M EBITDA contract manufacturing with diversified customers and strong industrial fundamentals.

Archetype 3: end-market specialist PE. Aerospace CDMO buyers (AE Industrial Partners, Liberty Hall Capital, Arlington Capital Partners) for aerospace-mix CDMOs. Medical device CDMO buyers (Linden Capital Partners, Patient Square Capital, LaSalle Capital) for medical-mix CDMOs. Multiples: 7-12x EBITDA depending on end-market and certification depth. Best fit: $3M+ EBITDA CDMOs with deep end-market mix and current certifications.

Archetype 4: PE add-on / tuck-in. Existing PE-backed contract manufacturing platforms acquiring smaller bolt-ons. Same named PE firms operating through portfolio companies. Multiples: 5-7x EBITDA, often with rollover equity. Faster close (60-120 days). Best fit: $1-7M EBITDA contract manufacturing with capability or customer fit to existing platform.

Archetype 5: strategic / vertical integrator. Larger contract manufacturers acquiring smaller competitors for capability or capacity. OEM customers vertically integrating their supply base (less common but happens). Multiples: 5-8x EBITDA when synergies are real. Best fit: contract manufacturers with specific capability that complements a larger acquirer’s platform or that an OEM customer wants to insource.

Buyer type	Cash at close	Rollover equity	Exclusivity	Best fit for
Strategic acquirer	High (40–60%+)	Low (0–10%)	60–90 days	Sellers who want a clean exit; competitor or upstream consolidator
PE platform	Medium (60–80%)	Medium (15–25%)	60–120 days	Sellers willing to hold rollover for the second sale; bigger deals
PE add-on	Higher (70–85%)	Low–Medium (10–20%)	45–90 days	Sellers folding into existing platform; faster process
Search fund / ETA	Medium (50–70%)	High (20–40%)	90–180 days	Legacy-conscious sellers wanting an owner-operator successor
Independent sponsor	Medium (55–75%)	Medium (15–30%)	60–120 days	Sellers OK with deal-by-deal capital and longer financing closes

Named PE platforms acquiring contract manufacturing in 2026

Contract-manufacturing-active PE platforms with verifiable 2025-2026 deals. Audax Industrial Partners — deep LMM industrial with multiple contract manufacturing platforms across precision components, engineered products, and CDMO categories. KKR Industrials — large-cap industrial portfolio with contract manufacturing exposure including major CDMO platforms. Cortec Group — industrial distribution and contract manufacturing platforms. Sterling Group — basic industrial including contract manufacturing. Wynnchurch Capital, Mason Wells, GenNx360, IGP, Trive Capital, Arsenal Capital — all active in contract manufacturing across industrial sub-segments.

End-market specialists for aerospace CDMOs. AE Industrial Partners — pure-play aerospace; aerospace CDMOs with AS9100D and Tier-1 OEM mix are core thesis. Liberty Hall Capital Partners — aerospace and defense supply chain including CDMO platforms. Arlington Capital Partners — aerospace, defense, government services with CDMO exposure.

End-market specialists for medical device CDMOs. Linden Capital Partners (Chicago) — healthcare specialist with multiple medical device CDMO platforms. Patient Square Capital — healthcare-focused with medical CDMO exposure. LaSalle Capital — LMM healthcare specialist with CDMO investments. Premium multiples (8-12x) for ISO 13485 + FDA-registered CDMOs with diversified customers and recurring consumables / disposables work.

Family offices with industrial / contract manufacturing mandates. Many of the 76+ buyers we work with include family offices investing in contract manufacturing. They typically pay 0.5-1x below institutional PE but offer longer hold periods, lighter operational change, rollover equity options. Best fit for owner-operators who care about legacy, employee continuity, and customer relationship preservation more than peak multiple.

The typical contract manufacturing M&A sale process

A contract manufacturing sell-side process for a $3M+ EBITDA business runs 9-12 months from prep-complete to close. Slightly longer than generic manufacturing because of the depth of customer concentration analysis, contract review, and customer-side change-of-control provisions. Add 12-18 months on the front for proper preparation if customer diversification, multi-year contracts, and IP ownership clarity aren’t in place.

Months 1-2: positioning, CIM build, buyer list. Build a 40-60 page CIM emphasizing customer concentration profile (top 10 customers with revenue percentages, contract structure, tenure), end-market mix, certification depth (ISO 9001, AS9100D, ISO 13485, ITAR), process / IP differentiation, recurring volume vs project work, and growth thesis. Build a target buyer list of 25-50 prospects: 50-60% generalist industrial PE and contract-mfg-active PE platforms, 15-25% end-market specialists for aerospace / medical / defense mix, 10-15% PE add-ons via portfolio companies, 10-15% family offices.

Months 2-4: management meetings and IOIs. 8-12 buyers move into management presentations — typically a half-day on-site visit including operations walkthrough, customer concentration / contract review, certification audit, IP discussion, and Q&A. Receive 3-7 IOIs. Negotiate to 2-3 buyers for confirmatory diligence.

Months 4-8: LOI, exclusivity, confirmatory diligence. Sign LOI with 60-90 day exclusivity. QoE engagement ($75-150K). Customer reference calls (carefully managed — particularly important in CMG to validate customer relationship strength and renewal probability). Contract review by buyer’s legal counsel (assignment provisions, change-of-control, indemnification). IP ownership review. Working capital target negotiation. Indemnification, R&W, escrow, earnout terms negotiated.

Months 8-12: signing, close, transition. Definitive purchase agreement signed. Customer notifications per contractual requirements. Regulatory clearance (HSR if applicable). Final working capital adjustment. Employee notification. Closing — wire transfer, escrow funding, transition services agreement effective. Many contract manufacturing deals include 12-24 month transition services agreements covering customer relationship management.

Contract-manufacturing-specific timeline disruptors. Customer-side change-of-control provisions can require customer consent before close. Customer reference calls during diligence can surface concerns that re-trade the deal. Contract assignment-restriction clauses can require renegotiation. IP ownership ambiguity (especially if customers contributed designs, tooling, or process IP) can derail the deal. Single-source supplier exposure for the buyer (your specialty process is the only qualified source) can be a positive but also creates buyer concern about ongoing dependence.

What drives premium multiples in contract manufacturing

Six characteristics drive 4.5x vs 7.5x outcomes in contract manufacturing M&A. Each is a structural driver of buyer underwriting. Customer diversification compounds with multi-year contracts compounds with end-market mix — a contract manufacturer with all six characteristics trades 2-3 turns above one with concentrated customers and project-based work.

Driver 1: customer diversification. Top customer below 20% of revenue. Top 5 customers below 65%. Top 10 customers below 85%. Diversification across multiple end-markets if possible. This is the single most important multiple driver in contract manufacturing — worth 1-2x within band.

Driver 2: multi-year supply agreements. Multi-year Master Supply Agreements with anchor customers (3-7 year terms with auto-renewal). Volume commitments where possible. Pricing escalators. Assignment provisions that allow transfer to acquirer without customer consent. Documented in CIM with contract list.

Driver 3: end-market certifications matched to customer mix. AS9100D for aerospace. ISO 13485 for medical device. ITAR for defense. ISO 9001 baseline. NADCAP for special processes. Certifications must match customer mix — an ISO 13485 certification is wasted on commercial industrial customers. Document certifications and their alignment with customer end-markets.

Driver 4: proprietary process IP. Validated processes that customers depend on. Trade secrets in setup, fixturing, programming. Patents on specific manufacturing methods. PMA approvals for medical device aftermarket. Documented IP increases multiple 0.5-1x. Pure build-to-print with no proprietary content trades at the bottom of band.

Driver 5: recurring volume vs project-based. Predictable monthly / quarterly volume from established customers is premium. Spot-buy / project-based work is discount. Forecasted backlog at 12+ months of revenue is premium. PE platforms model recurring volume more favorably than project-based revenue.

Driver 6: second-tier operations leadership. Operations VP, quality VP, sales / customer relationship VP who survive the owner’s departure. Customer relationships that span multiple contacts beyond the owner. Documented operational processes. Programming / engineering depth distributed across multiple employees, not concentrated in the owner.

Common deal-killers in contract manufacturing diligence

Five issues kill or re-trade more contract manufacturing LOIs than any others. Each is preventable with 12-18 months of pre-process preparation. Each is also discovered late in diligence by 90% of unprepared sellers. The economic asymmetry of fixing them in advance is enormous.

Deal-killer 1: top customer concentration above 30%. The single biggest deal-killer in contract manufacturing. Above 30%, multiples compress 0.5-1.5x or the deal moves to earnout structures tied to customer retention. Above 40%, many PE platforms walk. Above 50%, the deal is essentially priced as customer-replacement risk. The 12-18 month fix: aggressive new-customer development, intentional volume rebalancing, multi-year contract formalization.

Deal-killer 2: contract assignment-restriction clauses. Customer contracts with anti-assignment clauses or change-of-control termination rights require customer consent before transfer. Customers can use this leverage to extract pricing concessions or even refuse consent. The fix: 12-18 months of contract renegotiation to add assignment provisions, or pre-process customer outreach to confirm consent for transfer to a financial buyer.

Deal-killer 3: customer-side change-of-control provisions. Many large OEM customers (especially Tier-1 aerospace, medical device, automotive) have change-of-control provisions in their supply agreements that can trigger requalification, audit, or termination. The fix: review all customer contracts 18-24 months ahead. Address change-of-control provisions through renegotiation where possible. Document buyer-friendly provisions in CIM.

Deal-killer 4: IP ownership ambiguity. If customers contributed designs, tooling, fixturing, or process IP that’s now embedded in your operations, IP ownership can be ambiguous. Customer-owned tooling on your floor must be properly documented. Process IP developed jointly with customers may have customer ownership claims. The fix: pre-process IP audit with intellectual property counsel. Document ownership rigorously. Address ambiguity through customer agreements before market.

Deal-killer 5: regulatory compliance gaps. Open Form 483 observations for medical CDMOs. Lapsed AS9100 for aerospace CDMOs. ITAR registration issues for defense CDMOs. ISO 9001 audit findings. Each can compress multiples or kill the deal. Fix: pre-process compliance audit by external counsel and quality consultant 12+ months ahead.

How CT Acquisitions works: a buy-side partner, not a sell-side broker

Most M&A advisors are sell-side brokers. They sign you to a 12-month exclusive engagement, charge a monthly retainer, run a competitive auction process across 6-12 months, and collect a success fee (typically 5-10% of deal value, often $500K-$1.5M+ on a $10-20M contract manufacturing deal). The economics are heavily front-loaded for the broker.

We work the other side of the table. We’re a buy-side partner working with 76+ active U.S. lower middle market buyers, including 38 manufacturing-focused capital partners. On the contract manufacturing side specifically, we work with the named PE platforms (Audax Industrial, KKR Industrials, Cortec, Sterling Group, Wynnchurch, Mason Wells, GenNx360, IGP, Trive, Arsenal) plus end-market specialists (aerospace: AE Industrial, Liberty Hall, Arlington; medical device: Linden, Patient Square, LaSalle). The buyers pay us when a deal closes, not you. No retainer. No exclusivity. No 12-month contract. No tail fee.

Why this works for contract manufacturing owners. Customer concentration is the most variable driver of multiples in contract manufacturing — and the right buyer for a 35%-concentration business is different from the right buyer for a 15%-concentration business. We already know which of the 76+ buyers will engage at your concentration level and end-market mix. We can introduce you to 3-5 buyers with active mandates that fit your business in days, not months. We move faster (60-120 days from intro to LOI) because we already know who the right buyer is. The cost-of-trying is zero.

When a sell-side broker is the better fit. If your business is $30M+ EBITDA contract manufacturing with diverse customers, multiple plausible strategic buyers, and clear synergies in the strategic case, a top-tier sell-side investment bank may justify the fees. For LMM contract manufacturing ($1-30M EBITDA), the buy-side path almost always delivers better economics.

Conclusion

Contract manufacturing M&A in 2026 is dominated by customer concentration as the #1 multiple driver. 76+ active LMM buyers, 38 manufacturing-focused, including contract-mfg-active PE platforms (Audax Industrial, KKR Industrials, Cortec Group) and broader generalist industrial PE (Sterling Group, Wynnchurch, Mason Wells, GenNx360, IGP, Trive Capital, Arsenal Capital), plus end-market specialists for aerospace CDMOs (AE Industrial, Liberty Hall, Arlington Capital) and medical device CDMOs (Linden Capital, Patient Square, LaSalle Capital). Multiples by size: $1-3M = 4-5.5x; $3-7M = 5-6.5x; $7-15M = 5.5-7.5x; $15M+ = 6.5-8.5x. The premium drivers are clear: customer diversification (top customer <20%), multi-year supply agreements with assignment provisions, end-market certifications matched to customer mix, proprietary process IP, recurring volume rather than project work, second-tier operations leadership. The deal-killers are equally clear: top customer concentration above 30%, contract assignment-restriction clauses, customer-side change-of-control provisions, IP ownership ambiguity, regulatory compliance gaps. Owners who prepare 12-18 months ahead and position to the right buyer archetype see 1-2 turns of multiple uplift. If you want to talk to a buy-side partner who already knows the 76+ buyers and the contract-mfg-active platforms specifically, we’re a buy-side partner — the buyers pay us, not you, no contract required.

Frequently Asked Questions

What is my contract manufacturing business worth in 2026?

Generic ranges by EBITDA: $1-3M = 4-5.5x; $3-7M = 5-6.5x; $7-15M = 5.5-7.5x; $15M+ = 6.5-8.5x. Customer concentration adjustments: top customer above 30% subtracts 0.5-1.5x, top customer above 40% triggers earnout structures. End-market adjustments: aerospace CDMO +1-2x, medical CDMO +1-3x, defense +0.5-1.5x.

Why is customer concentration the #1 issue in contract manufacturing M&A?

Because revenue belongs to the customer, not the manufacturer. If a Tier-1 OEM insources, dual-sources, or moves volume, your revenue moves with them. Buyers underwrite this risk explicitly. Top customer above 30% triggers 0.5-1.5x multiple compression and/or earnout structures tied to customer retention. Customer diversification is the single most valuable 12-18 month preparation work in contract manufacturing.

Who buys contract manufacturing businesses in 2026?

Five archetypes: contract-mfg-active PE platforms (Audax Industrial, KKR Industrials, Cortec Group), generalist industrial PE (Sterling Group, Wynnchurch, Mason Wells, GenNx360, IGP, Trive Capital, Arsenal Capital), end-market specialists (aerospace: AE Industrial, Liberty Hall, Arlington; medical: Linden, Patient Square, LaSalle), PE add-ons via portfolio companies, and family offices with industrial mandates.

How do contract assignment clauses affect a sale?

Customer contracts with anti-assignment or change-of-control termination clauses require customer consent before transfer. Customers can use this leverage to extract pricing concessions or refuse consent. The 12-18 month fix: contract renegotiation to add assignment provisions, or pre-process customer outreach to confirm consent for transfer to a financial buyer.

What about customer-side change-of-control provisions?

Large OEM customers (Tier-1 aerospace, medical device, automotive) often have change-of-control provisions in supply agreements that can trigger requalification, audit, or termination. Review all customer contracts 18-24 months ahead. Address provisions through renegotiation where possible. Document buyer-friendly provisions in CIM.

How long does a contract manufacturing sale process take?

9-12 months from prep-complete to close for a $3M+ EBITDA contract manufacturing business. Slightly longer than generic manufacturing because of customer concentration analysis depth, contract review, customer-side change-of-control review, and IP ownership analysis. Add 12-18 months for proper preparation if customer diversification, multi-year contracts, and IP clarity aren’t in place.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 8-12% of the deal (often $500K-$1.5M+) plus monthly retainers and require 12-month exclusivity. We work directly with 76+ buyers including 38 manufacturing-focused capital partners and contract-mfg-active PE platforms (Audax, KKR Industrials, Cortec) plus end-market specialists. The buyers pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract. We move faster (60-120 days from intro to LOI) because we already know who the right buyer is at your customer concentration level.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. U.S. Small Business Administration — Buying & Selling a Business
2. Audax Group — Industrial Investments Portfolio
3. KKR — Private Equity Investment Strategy
4. Cortec Group — Industrial Investment Strategy
5. AE Industrial Partners — Aerospace Portfolio
6. Linden Capital Partners — Healthcare Investment Strategy
7. National Association of Manufacturers — State of Manufacturing
8. PitchBook — U.S. PE Middle Market Report